Halozyme Therapeutics (HALO) Tops Q3 EPS by 4c

Halozyme Therapeutics (NASDAQ: HALO) reported Q3 EPS of ($0.19), $0.04 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.6 million versus the consensus estimate of $30.42 million.

GUIDANCE:

Halozyme Therapeutics sees FY2018 revenue of $150-160 million, versus the consensus of $127.8 million.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79